Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb

NCT00003759 is registered in ClinicalTrials.gov with Anthra Pharmaceuticals as lead sponsor.

NCT NCT00003759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravesical Treatment of Superficial Bladder Cancer Characterized on the Basis of the Tumor Markers p53 and pRb
Lead sponsor
Anthra Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 1998
Completion date
November 30, 2002
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer